Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we write to inform you that a conference call to discuss the Q1FY20 financial results will be held on Tuesday, 13th August, 2019 at 11.00 A.M. Please find attached herewith the conference call details. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Board Meeting Intimation for Notice Of Meeting Of Board Of Directors Of Alkem Laboratories Limited ('The Company")
Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2019 ,inter alia, to consider and approve To consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2019. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 and 47 read alongwith Schedule Ill of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulation"}, please find enclosed herewith a copy of advertisement published in today''s Newspapers viz. Business Standard (English) and Lakshadweep (Marathi) informing about completion of despatch of Notice of the 45th AGM alongwith Annual Report for the FY 2018-19 and availability of e-voting facility to the shareholders. The same is also available on the website of the Company at www.alkemlabs.com
Alkem Labs gets EIR from FDA for Baddi plant
The US FDA has issued an Establishment Inspection Report (EIR) for Alkem Laboratories' manufacturing facility located at Baddi, India which was inspected from 13th May, 2019 to 11 May 2019. Alkem Labs had earlier received a Form 483 issued by the US FDA containing four observations, and the company had submitted a corrective and preventive action (CAP A) plan to the regulator within the stipulated timelines. The inspection has now been closed by the US FDA, with the EIR. To see all FDA search results in filings, try Discover. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
In furtherance to the intimation captioned "US FDA Inspection at Alkem's manufacturing facility located at Baddi, India" dated 17th May, 2019, this is to inform you that US FDA has issued an Establishment Inspection Report (EIR) for the Company's manufacturing facility located at Baddi, India which was inspected from 13th May, 2019 to 17th May, 2019. In response to the Form 483 issued by the US FDA containing four observations, the Company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines. The inspection has now been closed by the US FDA. Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Reg. 34 (1) Annual Report
Please find enclosed herewith the Notice of the 45th Annual General Meeting of the Company scheduled to be held on Tuesday, 27th August, 2019 at 10.30 a.m. at Nehru Centre Auditorium, Dr. Annie Besant Road, Worli, Mumbai - 400 018 alongwith the Annual Report for the financial year 2018-2019. The same is also available on the website of the Company at www.alkemlabs.com Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Demise
Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 we would like to inform you that the Company''s Founder and Chairman Emeritus of the Board of Directors of the Company, Shri Samprada Singh expired today morning. Kindly take note of the above. Alkem Laboratories Ltd - 539523 - Shareholding for the Period Ended June 30, 2019
Alkem Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2019. For more details, kindly Click here Alkem Laboratories Ltd - 539523 - Statement Of Investor Complaints For The Quarter Ended June 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Mr. Manish NarangDesignation :- Company Secretary and Compliance Officer Alkem Laboratories Ltd - 539523 - Closure of Trading Window
This is to inform you that in terms of Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window will remain closed from 29th June, 2019 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter ended 30th June, 2019 are communicated to the Stock Exchanges.